Syntaxin's Series A Round

Syntaxin raised a round of funding on November 14, 2005. Investors include Abingworth.

Syntaxin discovers and develops a new class of biopharmaceuticals, Targeted Secretion Inhibitors (TSIs) that treat disease through selective inhibition of cell secretory pathways. It is developing TSI…

Articles about Syntaxin's Series A Round: